Skip to main content
. 2022 Aug 3;140(17):1845–1857. doi: 10.1182/blood.2021014586

Table 3.

Events occurring in ≥20% of patients in either treatment group

AE GIL + AZA (n = 73)
AZA (n = 47)
All grades Grade ≥ 3 All grades Grade ≥ 3
Overall 73 (100.0) 70 (95.9) 43 (91.5) 42 (89.4)
Pyrexia 35 (47.9) 7 (9.6) 16 (34.0) 0
Diarrhea 28 (38.4) 5 (6.8) 8 (17.0) 0
Febrile neutropenia 26 (35.6) 26 (35.6) 10 (21.3) 9 (19.1)
Constipation 25 (34.2) 0 10 (21.3) 0
Nausea 24 (32.9) 1 (1.4) 10 (21.3) 1 (2.1)
Anemia 23 (31.5) 18 (24.7) 16 (34.0) 13 (27.7)
Thrombocytopenia 22 (30.1) 20 (27.4) 11 (23.4) 9 (19.1)
Pneumonia 19 (26.0) 15 (20.5) 8 (17.0) 8 (17.0)
Neutropenia 18 (24.7) 16 (21.9) 13 (27.7) 10 (21.3)
Aspartate aminotransferase increased 18 (24.7) 4 (5.5) 3 (6.4) 0
Vomiting 18 (24.7) 2 (2.7) 8 (17.0) 0
Asthenia 17 (23.3) 5 (6.8) 7 (14.9) 0
Edema peripheral 16 (21.9) 0 5 (10.6) 0
Hypokalemia 16 (21.9) 6 (8.2) 10 (21.3) 4 (8.5)
Decreased appetite 15 (20.5) 3 (4.1) 7 (14.9) 1 (2.1)
Neutrophil count decreased 14 (19.2) 14 (19.2) 4 (8.5) 4 (8.5)
Platelet count decreased 14 (19.2) 13 (17.8) 9 (19.1) 9 (19.1)
Hyponatremia 14 (19.2) 9 (12.3) 3 (6.4) 1 (2.1)
Sepsis 4 (5.5) 4 (5.5) 5 (10.6) 5 (10.6)

Including AEs of grade ≥3 severity occurring in at least 10% of patients in either treatment group.